Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced that its management team will participate in a fireside chat and one-on-one meetings at the Cantor 2026 Global Healthcare Conference, scheduled for September 9-11, 2026, in New York. President and CEO Seth Lederman, M.D., will present on September 10 from 3:55-4:25 p.m. ET. A live webcast and replay will be available through the Investors section of the Tonix website.
This appearance comes at a critical time for Tonix as the company seeks to capitalize on the recent approval of TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), the first new treatment for fibromyalgia in over 15 years. The approval marks a significant milestone for the company, which is now a fully-integrated, commercial-stage biotechnology firm. Tonix's focus on central nervous system (CNS) and immunology treatments addresses areas of high unmet medical need, positioning the company for potential growth in a competitive market.
The conference participation offers Tonix an opportunity to communicate its strategic vision to investors and industry stakeholders. The company's CNS commercial infrastructure supports its marketed products, including its acute migraine treatments Zembrace SymTouch and Tosymra. Beyond TONMYA, Tonix is exploring the drug's potential in Phase 2 clinical trials for major depressive disorder and acute stress disorder, indicating a broader application for the therapy.
Tonix's pipeline includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare genetic disorder. In immunology, the company is advancing monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor aimed at preventing kidney transplant rejection. These programs underscore Tonix's commitment to addressing serious conditions with limited treatment options.
The company's participation in the Cantor conference is a strategic move to highlight its progress and future prospects. For investors, the presentation could provide insights into the company's commercial strategy for TONMYA and its pipeline developments. The live webcast and replay availability ensure broad access for shareholders and interested parties.
As Tonix continues to integrate its commercial operations and advance its research, the upcoming conference presentation will be an important platform to showcase the company's achievements and roadmap. With a robust pipeline and a recently launched product, Tonix is positioned to make significant strides in the biotechnology sector.
